Crystalline Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Crystalline Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-230,817	Closed	-$294K	–	140
2023 Q3	$294K	Buy	+230,817	New	+$202K	0.21%	71

Crystalline Management's ZYNE Position: Q4 2023 in Review

Crystalline Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 230,817 shares — an estimated $294K sold.

Crystalline Management first reported a position in ZYNE in Q3 2023 and held it in 1 quarter. The position peaked at $294K in Q3 2023. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.

Crystalline Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
Crystalline Management sold 230,817 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $294K.
Crystalline Management first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2023 and held it in 1 quarter.
Crystalline Management's Zynerba Pharmaceuticals, Inc position peaked at $294K in Q3 2023.
0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.

Based on Crystalline Management's 13F filing for Q4 2023, filed 12 Feb 2024.